Market Leader Intermediate Test File Pdf

[Malka Sedano]

Ina recent study of 718 men presented at the American Society of Clinical Oncology Genitourinary Cancer Symposium in San Francisco, Myriad demonstrated the ability of Prolaris to predict which prostate cancer patients with unfavorable intermediate or high-risk disease would benefit from additional treatment. In the study, patients above the high-risk threshold saw a statistically significant benefit from multi-modality therapy leading to a reduction in the risk of metastases where patients below the high-risk threshold saw no statistical benefit from additional treatment and could avoid the morbidity associated with increased therapy.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prequel, ForeSight, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Rajasri Chandra, MS, MBA is a global marketing leader with expertise in managing upstream, downstream, strategic, tactical, traditional, and digital marketing in biotech, in vitro diagnostics, life sciences, and pharmaceutical industries. Raj is an orchestrator of go-to-market strategies driving complete product life cycle from ideation to commercialization.

Producing accurate color on paper can be difficult. Balancing the complexities of the raw materials like chemicals, fillers, dyes, pigments, OBAs and other materials required to produce the pulp is one thing, while also accommodating other customer specifications and operational needs, is another. Not to mention the environmental factors like a dirty environment or product temperature that can impact the color. Properly producing accurate color from pulp to final inspection requires a smart, stable, reliable, and accurate inline color measurement system that provides early warnings of color shifts at critical checkpoints on the production line.

Attend this TAPPI-hosted webinar to hear from X-Rite's inline color experts as well as a guest speaker on how X-Rite's industry-leading inline closed-loop color control solutions gives you the data and automation you need to achieve total color control on your production line(s), improve overall production output and quality, and achieve a quick ROI.

Manfred Binder is the Director for New Business Development for Inline Color Measurement at X-Rite GmbH, the market leader for color measurement. After his graduation in mechanical engineering, he collected experience with optical instruments. In the last 35 years he worked in the color business in different roles. For more than 25 years he has been in the inline color business where he consults many different industries all around the world. His idea is that only color measurement in the process helps to avoid off spec production

The test accurately identified a group of women whose cancers are so likely to respond to hormone-blocking drugs that adding chemo would do little if any good while exposing them to side effects and other health risks. In the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.

A California company, Genomic Health Inc., has sold a test called Oncotype DX since 2004 to help gauge this risk. The test measures the activity of genes that control cell growth, and others that indicate a likely response to hormone therapy treatment.

Past studies have looked at how women classified as low, intermediate or high risk by the test have fared. The new study is the first to assign women treatments based on their scores and track recurrence rates.

Dr. Karen Beckerman, a New York City obstetrician diagnosed with breast cancer in 2011, said she was advised to have chemo but feared complications. A doctor suggested the gene test and she scored very low for recurrence risk.

The test costs $4,175, which Medicare and many insurers cover. Others besides Oncotype DX also are on the market, and Hudis said he hopes the new study will encourage more, to compete on price and accuracy.

Industry-Leading Open Format for the Exchange of 3D Assets Supporting New Compliance Opportunities; OpenCOLLADA Support for 3ds Max & Maya; Dassault Systemes Announces Broad Support for COLLADA, Integration with Google, EA, Blender & Yumetech

COLLADA defines an XML-based schema making it simple to transport 3D assets between applications - enabling diverse 3D authoring and content processing tools to be easily combined into a production pipeline. As an intermediate language, The COLLADA schema provides comprehensive encoding of visual scenes including: geometry, shaders and effects, physics, animation, kinematics, and even multiple version representations of the same asset. COLLADA FX enables leading 3D authoring tools to work effectively together to create shader and effects applications and assets to be authored and packaged using OpenGL Shading Language, Cg, CgFX, and DirectX FX. The Khronos Group has also made the COLLADA 1.5 specification and release notes available in Japanese at

After one year of Beta, NetAllied Systems finally released the next generation of COLLADA exporters and importers for Autodesk 3ds Max and Autodesk Maya built on the latest OpenCOLLADA SDK. OpenCOLLADA plug-ins are available for immediate download at

The Khronos COLLADA WG also announced today the availability of the first release of the OpenCOLLADA framework to fully support the reading and writing of COLLADA 1.4.1 and 1.5.0 files. Further performance improvements and minor bug fixes have been included. MathML support (required for Kinematics) is available as well. Downloads are available at

Based on their years of experience in working with 3D and open source software, for 3D graphics development, Yumetech is developing the Test Suite on-time with a wide range of additional test cases and is currently entering closed beta with Khronos members that include Autodesk Inc. The company has prior experience developing portions of the X3D conformance suite and is a current member of Khronos and participates in the COLLADA work group.

As market leaders in the testing and certification of respiratory products, we work with some of the best known manufacturers in this field to help bring their products to market. Our team of testing experts are based at our center of excellence Kitemark House, and our recently refurbished testing laboratories contain state of the art test rigs.

We can help you to gain European market access as all respiratory equipment must undergo type examination using a Notified Body such as BSI before CE Marking can be affixed. To differentiate your products we can also help you to gain BSI Kitemark certification, one of the best known independent marks of quality.

Advances in the technology of respiratory products mean that they may now incorporate headwear, eyewear or hearing protection and some products may also incorporate electronic devices. We can provide a complete testing solution for these requirements to help you be compliant and with your product development requirements.

Excessive noise is prevalent in many industries as well as personal pursuits. The Control of Noise at Work Regulations 2005 places the level at which employers must provide hearing protection and hearing protection zones at 85 decibels (average/daily exposure). The level at which employers must make a workers' risk assessment and provide information and training is now 80 decibels. There is also a ceiling of 87 decibels (taking into account hearing protection) above which workers should not be exposed.

We can test a wide range of hearing protection equipment to ensure compliance with the Personal Protective Equipment Directive 89/686. We can also provide BSI Kitemark certification for these products to help you demonstrate the quality and differentiate your products.

Whether you are just starting out on your business improvement journey, or looking to enhance your current knowledge and capabilities, contact our expert team who will be able to give advice and guidance about options that will enable you to meet your goals.

Impartiality is the governing principle of how BSI provides its services. Impartiality means acting fairly and equitably in its dealings with people and in all business operations. It means decisions are made free from any engagements of influences which could affect the objectivity of decision making.

As an accredited certification body, BSI Assurance cannot offer certification to clients where they have also received consultancy from another part of the BSI Group for the same management system. Likewise, we do not offer consultancy to clients when they also seek certification to the same management system.

The British Standards Institution (BSI, a company incorporated by Royal Charter), performs the National Standards Body (NSB) activity in the UK. BSI, together with its Group Companies, also offers a broad portfolio of business solutions other than NSB activity that help businesses worldwide to improve results through Standards-based best practice (such as certification, self-assessment tool, software, product testing, information products and training).

3a8082e126